Elsevier Announces Publishing The Ocular Surface
New York, NY, January 19, 2012 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce newly acquiring The Ocular Surface, a peer-reviewed journal focusing on the external eye and vision. As per January 2012 Elsevier will continue the publication of the quarterly journal.
The Ocular Surface delivers reviews of important work in laboratory science, clinical science, and clinical practice related to the external eye and vision, along with coverage of ongoing studies, patents pending, conference highlights, and more. The Ocular Surface has an Impact Factor of 3.103 and is ranked 7th out of 56 journals in the Ophthalmology category according to the 2011 Journal Citation Reports© published by Thomson Reuters. The journal has remained in the top 10 ranking of Impact Factors for the last three years.
Gary N. Foulks, MD, Editor-in-Chief of The Ocular Surface said of the acquisition, “We are very pleased to start working with Elsevier. Together we will bring The Ocular Surface to a new level of excellence in serving our professional community.”
“Elsevier is truly honored to publish The Ocular Surface. This premier journal represents innovative, high-quality content, and is an excellent addition to our leading ophthalmology journals program,” Nancy Axelrod, Executive Publisher at Elsevier added.
# # #
About The Ocular Surface
The Ocular Surface, a quarterly, a peer-reviewed journal, is an authoritative resource that integrates and interprets major findings in diverse fields related to the ocular surface, including ophthalmology, optometry, genetics, molecular biology, pharmacology, immunology, infectious disease, and epidemiology. Its critical review articles cover the most current knowledge on medical and surgical management of ocular surface pathology, new understandings of ocular surface physiology, the meaning of recent discoveries on how the ocular surface responds to injury and disease, and updates on drug and device development.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+ 1 215 239 3658